BMC cardiovascular disorders · 2025
Clinical efficacy of sacubitril/valsartan combined with cardiac rehabilitation in patients with heart failure after acute myocardial infarction: a single-center randomized trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Yan-Mei, Luo Jun-Ting, Pang Kai-Fang, Feng Ying, Tan Jian-Ping, Liu Ming, Lin Zhi-Hai
Аннотация
OBJECTIVE: To investigate the effect of sacubitril/valsartan (ARNI) combined with cardiac rehabilitation (CR) in patients with heart failure (HF) after acute myocardial infarction (AMI).
METHODS: A total of 118 patients with HF after AMI were screened and randomly divided into an experimental group and a control group. The control group was given ARNI. The experimental group received CR treatment in addition to the control treatment. The primary endpoint was cardiorespiratory fitness as measured by the cardiopulmonary exercise test (CPET). The secondary endpoints included cardiac remodeling detected by NT-ProBNP and cardiac ultrasound. All participants were assessed by CPET, NT-ProBNP, and cardiac ultrasound at baseline and after treatment.
RESULTS: After treatment, the changes in the left ventricular ejection fraction (LVEF), anaerobic threshold (AT), oxygen uptake peak (VO2 peak), and metabolic equivalents (METs) in the experimental group were significantly greater than those in the control group (all P < 0.05). However, there was no significant difference in BNP, Left atrial diameter (LA) or Left ventricular end diastolic diameter (LVD) between the two groups (P > 0.05).
CONCLUSIONS: Patients with HF after AMI could benefit from combined ARNI and CR.
TRIAL REGISTRATION: http://www.chictr.org.cn , ChiCTR2400093772 (11/12/2024). Retrospectively registered.
METHODS: A total of 118 patients with HF after AMI were screened and randomly divided into an experimental group and a control group. The control group was given ARNI. The experimental group received CR treatment in addition to the control treatment. The primary endpoint was cardiorespiratory fitness as measured by the cardiopulmonary exercise test (CPET). The secondary endpoints included cardiac remodeling detected by NT-ProBNP and cardiac ultrasound. All participants were assessed by CPET, NT-ProBNP, and cardiac ultrasound at baseline and after treatment.
RESULTS: After treatment, the changes in the left ventricular ejection fraction (LVEF), anaerobic threshold (AT), oxygen uptake peak (VO2 peak), and metabolic equivalents (METs) in the experimental group were significantly greater than those in the control group (all P < 0.05). However, there was no significant difference in BNP, Left atrial diameter (LA) or Left ventricular end diastolic diameter (LVD) between the two groups (P > 0.05).
CONCLUSIONS: Patients with HF after AMI could benefit from combined ARNI and CR.
TRIAL REGISTRATION: http://www.chictr.org.cn , ChiCTR2400093772 (11/12/2024). Retrospectively registered.
Предметные рубрики MeSH
HumansMaleAminobutyratesBiphenyl CompoundsFemaleValsartanHeart FailureMiddle AgedDrug CombinationsTreatment OutcomeRecovery of FunctionMyocardial InfarctionAgedVentricular Function, LeftCardiac RehabilitationVentricular RemodelingTime FactorsExercise ToleranceCardiorespiratory FitnessStroke VolumeAngiotensin II Type 1 Receptor BlockersBiomarkersNatriuretic Peptide, BrainProtease InhibitorsNeprilysinAngiotensin Receptor AntagonistsChinaPeptide Fragments